Ligand Pharmaceuticals (NASDAQ:LGND) Stock: Insider John Kozarich Sells 500 Shares

Ligand Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Ligand Pharmaceuticals director John Kozarich sold 500 shares for $162,500 at an average price of $325 under a pre-arranged Rule 10b5-1 plan. He retained 42,122 shares after the sale.
  • Ligand beat quarterly earnings and revenue estimates, reporting EPS of $2.67 versus $2.33 expected and revenue of $78.75 million versus $77 million; revenue was down 31.8% year over year.
  • Analysts give the stock a “Moderate Buy” consensus, with an average price target of $355.38. Shares were trading at $301.71 in the article’s report.
  • Interested in Ligand Pharmaceuticals? Here are five stocks we like better.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) Director John Kozarich sold 500 shares of the company's stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $325.00, for a total transaction of $162,500.00. Following the completion of the sale, the director owned 42,122 shares of the company's stock, valued at approximately $13,689,650. The trade was a 1.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ LGND traded down $7.08 during midday trading on Monday, reaching $301.71. The company's stock had a trading volume of 186,903 shares, compared to its average volume of 263,991. The stock has a market capitalization of $6.04 billion, a P/E ratio of 134.69, a PEG ratio of 5.39 and a beta of 1.16. The firm has a 50 day moving average price of $301.71 and a 200-day moving average price of $258.02. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19. Ligand Pharmaceuticals Incorporated has a 12-month low of $175.89 and a 12-month high of $326.63.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.33 by $0.34. The business had revenue of $78.75 million during the quarter, compared to the consensus estimate of $77.00 million. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The firm's quarterly revenue was down 31.8% compared to the same quarter last year. During the same quarter last year, the company posted $3.09 earnings per share. As a group, equities analysts predict that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.

Hedge Funds Weigh In On Ligand Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC increased its position in shares of Ligand Pharmaceuticals by 2.5% during the third quarter. Global Retirement Partners LLC now owns 1,403 shares of the biotechnology company's stock valued at $438,000 after acquiring an additional 34 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Ligand Pharmaceuticals by 5.7% in the second quarter. GAMMA Investing LLC now owns 681 shares of the biotechnology company's stock worth $215,000 after purchasing an additional 37 shares during the last quarter. Choreo LLC raised its stake in shares of Ligand Pharmaceuticals by 3.0% in the third quarter. Choreo LLC now owns 1,634 shares of the biotechnology company's stock worth $510,000 after purchasing an additional 47 shares during the last quarter. Cim Investment Management Inc. lifted its holdings in shares of Ligand Pharmaceuticals by 3.4% during the first quarter. Cim Investment Management Inc. now owns 1,484 shares of the biotechnology company's stock valued at $296,000 after purchasing an additional 49 shares in the last quarter. Finally, Ethic Inc. lifted its holdings in shares of Ligand Pharmaceuticals by 7.4% during the third quarter. Ethic Inc. now owns 1,002 shares of the biotechnology company's stock valued at $313,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 91.28% of the company's stock.

Wall Street Analyst Weigh In

LGND has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price target on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an "outperform" rating in a report on Friday, October 30th. Citigroup lifted their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. HC Wainwright reaffirmed a "buy" rating and set a $358.00 target price on shares of Ligand Pharmaceuticals in a report on Thursday, September 24th. Oppenheimer restated an "outperform" rating and issued a $326.00 price objective (up from $285.00) on shares of Ligand Pharmaceuticals in a report on Monday, August 3rd. Finally, Weiss Ratings cut shares of Ligand Pharmaceuticals from a "buy (b)" rating to a "hold (c)" rating in a report on Monday, November 2nd. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Ligand Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $355.38.

Check Out Our Latest Analysis on LGND

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Read More

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ligand Pharmaceuticals Right Now?

Before you consider Ligand Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.

While Ligand Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines